{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T03:59:26Z","timestamp":1789185566188,"version":"build-2803163510"},"reference-count":24,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T00:00:00Z","timestamp":1559260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>This study aims to assess the clinical efficacy and safety of ceftaroline for the treatment of complicated skin and skin structure infections (cSSSIs) in adult patients through meta-analysis. PubMed, Embase, ClinicalTrials.gov, and Cochrane databases were searched up to April 2019. Only randomized controlled trials (RCTs) that evaluated ceftaroline and other comparators for treating cSSSIs in adult patients were included. The primary outcome was the clinical cure rate, whereas the secondary outcomes were clinical failure rate, microbiological eradication rate, relapse rate, and risk of an adverse event (AE). Five RCTs were included. Overall, ceftaroline had a clinical cure rate similar to comparators in the treatment of cSSSIs in the modified intent-to-treat population (risk ratio (RR), 1.00; 95% confidence interval (CI), 0.97\u20131.04; I2 = 0%) and in the clinically evaluable population (RR, 1.00; 95% CI, 0.97\u20131.03; I2 = 0%). In addition, no significant difference was observed between ceftaroline and comparators for the treatment of infection with Staphylococcus aureus (RR, 1.01; 95% CI, 0.98\u20131.05; I2 = 0%), methicillin-resistant S. aureus (RR, 0.99; 95% CI, 0.94\u20131.05; I2 = 0%), methicillin-susceptible S. aureus (RR, 1.01; 95% CI, 0.96\u20131.06; I2 = 26%), Streptococcus spp. (RR, 1.07; 95% CI, 0.92\u20131.24; I2 = 73%), and Gram-negative bacteria (RR, 0.94; 95% CI, 0.83\u20131.08; I2 = 0%). Furthermore, ceftaroline had a similar rate of microbiological eradication (92.2% vs. 92.6%, RR, 1.00; 95% CI, 0.97\u20131.03; I2 = 9%) and relapse (6.9% vs. 9.1%, RR, 0.48; 95% CI, 0.14\u20131.74; I2 = 0%) as comparators. Finally, the risks of treatment-emergent AEs (RR, 0.96; 95% CI, 0.88\u20131.05; I2 = 0%), serious AEs (RR, 1.03; 95% CI, 0.63\u20131.68; I2 = 0%), and discontinuation of study drug due to an AE (RR, 0.86; 95% CI, 0.50\u20131.49; I2 = 34%) did not differ significantly between ceftaroline and comparators. In conclusion, the clinical efficacy of ceftaroline is as high as that of comparators in the treatment of cSSSIs in adult patients, and this antibiotic is well tolerated like the comparators.<\/jats:p>","DOI":"10.3390\/jcm8060776","type":"journal-article","created":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T11:59:56Z","timestamp":1559303996000},"page":"776","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Ceftaroline Efficacy and Safety in Treatment of Complicated Skin and Soft Tissue Infection: A Systemic Review and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8663-3161","authenticated-orcid":false,"given":"Shao-Huan","family":"Lan","sequence":"first","affiliation":[{"name":"School of Pharmaceutical Sciences and Medical Technology, Putian University, Putian 351100, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen-Peng","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Chi Mei Medical Center, Liouying 73657, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6334-2388","authenticated-orcid":false,"given":"Chih-Cheng","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Intensive Care Medicine, Chi Mei Medical Center, Liouying 73657, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Chin","family":"Lu","sequence":"additional","affiliation":[{"name":"School of Management, Putian University, Putian 351100, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Ming","family":"Chao","sequence":"additional","affiliation":[{"name":"Department of Intensive Care Medicine, Chi Mei Medical Center, Liouying 73657, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,5,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.3201\/eid1509.081228","article-title":"Trends in US hospital admissions for skin and soft tissue infections","volume":"15","author":"Edelsberg","year":"2009","journal-title":"Emerg. Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1093\/cid\/cix640","article-title":"Trends in methicillin-resistant Staphylococcus aureus hospitalizations in the United States, 2010\u20132014","volume":"65","author":"Klein","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Kaye, K.S., Patel, D.A., Stephens, J.M., Khachatryan, A., Patel, A., and Johnson, K. (2015). Rising United States hospital admissions for acute bacterial skin and skin structure infections: Recent trends and economic impact. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0143276"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S368","DOI":"10.1086\/533593","article-title":"Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus","volume":"46","author":"Stryjewski","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1093\/cid\/ciu296","article-title":"Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America","volume":"59","author":"Stevens","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1345\/aph.1Q225","article-title":"Ceftaroline fosamil: A novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus","volume":"45","author":"Jorgenson","year":"2011","journal-title":"Ann. Pharmacother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.clinthera.2012.02.025","article-title":"Ceftaroline fosamil: A cephalosporin with activity against methicillin-resistant Staphylococcus aureus","volume":"34","author":"Poon","year":"2012","journal-title":"Clin. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/INF.0000000000001477","article-title":"Ceftaroline activity tested against bacterial isolates causing community-acquired respiratory tract infections and skin and skin structure infections in pediatric patients from United States hospitals: 2012\u20132014","volume":"36","author":"Pfaller","year":"2017","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ijantimicag.2016.12.016","article-title":"In vitro activity of ceftaroline and comparator agents against Gram-positive and Gram-negative clinical isolates from cancer patients","volume":"49","author":"Rolston","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S206","DOI":"10.1093\/cid\/cis563","article-title":"In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: A review of published studies and the AWARE Surveillance Program (2008\u20132010)","volume":"55","author":"Farrell","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1089\/sur.2015.209","article-title":"Antimicrobial Activity of ceftaroline tested against Staphylococcus aureus from surgical skin and skin structure infections in US medical centers","volume":"17","author":"Sader","year":"2016","journal-title":"Surg. Infect."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S1473-3099(14)71018-7","article-title":"Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: A randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial","volume":"15","author":"Zhong","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/jac\/dkr096","article-title":"FOCUS 1: A randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"File","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/jac\/dkr097","article-title":"FOCUS 2: A randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"Low","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40121-019-0242-5","article-title":"Open-label randomized trial of early clinical outcomes of ceftaroline fosamil versus vancomycin for the treatment of acute bacterial skin and skin structure infections at risk of methicillin-resistant Staphylococcus aureus","volume":"8","author":"Claeys","year":"2019","journal-title":"Infect. Dis. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/jac\/dkq254","article-title":"CANVAS 1: The first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections","volume":"65","author":"Corey","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1093\/jac\/dkw333","article-title":"A Phase III, randomized, controlled, non-inferiority trial of ceftaroline fosamil 600 mg every 8 h versus vancomycin plus aztreonam in patients with complicated skin and soft tissue infection with systemic inflammatory response or underlying comorbidities","volume":"71","author":"Dryden","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1128\/AAC.00590-07","article-title":"Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections","volume":"51","author":"Talbot","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"iv53","DOI":"10.1093\/jac\/dkq255","article-title":"CANVAS 2: The second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections","volume":"65","author":"Wilcox","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s12931-018-0905-x","article-title":"Efficacy and effectiveness of Ceftaroline Fosamil in patients with pneumonia: A systematic review and meta-analysis","volume":"19","author":"Sotgiu","year":"2018","journal-title":"Respir. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"Bmj"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s11096-016-0417-z","article-title":"Ceftaroline fosamil for community-acquired pneumonia and skin and skin structure infections: A systematic review","volume":"39","author":"Turgeon","year":"2017","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e01043","DOI":"10.1128\/AAC.01043-17","article-title":"Antimicrobial susceptibility trends among Staphylococcus aureus isolates from U.S. Hospitals: Results from 7 Years of the Ceftaroline (AWARE) surveillance program, 2010 to 2016","volume":"61","author":"Sader","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1093\/jac\/dkv076","article-title":"Activity of ceftaroline and comparator agents tested against Staphylococcus aureus from patients with bloodstream infections in US medical centres (2009\u201313)","volume":"70","author":"Sader","year":"2015","journal-title":"J. Antimicrob. Chemother."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/8\/6\/776\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:55:08Z","timestamp":1760187308000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/8\/6\/776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,31]]},"references-count":24,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,6]]}},"alternative-id":["jcm8060776"],"URL":"https:\/\/doi.org\/10.3390\/jcm8060776","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,31]]}}}